Aptevo Therapeutics APVO

Aptevo Therapeutics announces clinical milestone for mipletamig

Item 8.01 Other events

Form
8-K
Filed
Importance
Routine
  1. Substantial reduction in infusion-related reactions (IRRs) with mipletamig
  2. Refined priming-dose regimen improves tolerability for frontline AML patients
  3. Mipletamig data to be presented at ASH 2026 meeting

Written from the 8-K on EDGAR. AI can make mistakes. Check the filing.

Get an email when Aptevo Therapeutics files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Companies of similar size in SIC 2834 and related industry codes: the same peer list as the financial tables.